Skip to main content
. 2023 Sep 5;53(11):775–786. doi: 10.4070/kcj.2023.0108

Table 1. Baseline characteristics.

Variables Total IPTW*
E2E (n=139) TVR (n=91) p value SMD E2E (n=138) TVR (n=89) p value SMD
Age (years) 61.2±12.5 58.6±12.1 0.106 0.219 60.5±12.8 60.7±12.3 0.918 0.016
Female 101 (72.7) 68 (74.7) 0.846 0.047 103 (74.6) 68 (76.4) 0.769 0.043
Body surface area (m2) 1.59±0.16 1.63±0.63 0.433 0.096 1.59±0.17 1.59±0.55 0.976 0.004
NYHA class 3–4 68 (48.9) 59 (64.8) 0.025 0.326 77 (55.8) 54 (60.7) 0.469 0.109
Hypertension 25 (18.0) 10 (11.0) 0.209 0.200 21 (15.1) 12 (13.5) 0.716 0.055
Diabetes mellitus 23 (16.5) 9 (9.9) 0.218 0.197 19 (13.8) 11 (12.4) 0.659 0.065
Stroke 10 (7.2) 2 (2.2) 0.173 0.238 7 (5.1) 4 (4.5) 0.849 0.033
Atrial fibrillation 99 (71.2) 78 (85.7) 0.017 0.358 107 (77.5) 71 (79.8) 0.636 0.073
COPD 3 (2.2) 0 (0.0) 0.414 0.210 2 (1.4) 0 (0.0) 0.172 0.163
Dialysis 2 (1.4) 0 (0.0) 0.672 0.171 2 (1.4) 0 (0.0) 0.266 0.186
EuroSCORE (%) 4.0±4.6 4.5±4.7 0.415 0.110 4.1±4.8 4.3±4.2 0.777 0.038
Previous OHS 35 (25.2) 25 (27.5) 0.815 0.052 41 (29.7) 19 (21.3) 0.228 0.172
LVEF ≤40% 17 (12.2) 4 (4.4) 0.075 0.287 13 (9.4) 10 (11.2) 0.747 0.063
TAD (cm) 4.23±0.58 4.24±0.59 0.939 0.010 4.23±0.59 4.21±0.56 0.809 0.035

Values are presented as mean ± standard deviation or number (%).

COPD = chronic obstructive pulmonary disease; E2E = edge-to-edge repair; IPTW = inverse probability of treatment weighting; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; OHS = open heart surgery; SMD = standardized mean difference; TAD = tricuspid annular diameter; TVR = tricuspid valve replacement.

*Counts in the weighted cohort may not sum to the expected totals due to rounding. Percentages may not total 100 because of rounding, and disagreements between numbers and percentages in the weighted cohort are the result of rounding of noninteger number values.